|
Nature of Business (Details) (USD $)
|
12 Months Ended |
|
|
|
|
Dec. 31, 2014
Program
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
| Nature of Business [Abstract] |
|
|
|
|
| Number of programs in clinical development for cancer indications |
2 |
|
|
|
| Estimated Projected Expenditure Type [Line Items] |
|
|
|
|
| Cash and cash equivalents |
$ 32,218,905 |
$ 11,483,112 |
$ 14,344,088 |
$ 17,988,590 |
| Short-term investments |
45,621,593 |
27,084,980 |
|
|
| Projected expenditures for clinical programs |
58,600,000 |
|
|
|
| Aldoxorubicin [Member] |
|
|
|
|
| Estimated Projected Expenditure Type [Line Items] |
|
|
|
|
| Projected expenditures for clinical programs |
43,900,000 |
|
|
|
| Albumin-Binding Cancer Drugs [Member] |
|
|
|
|
| Estimated Projected Expenditure Type [Line Items] |
|
|
|
|
| Projected expenditures for clinical programs |
2,000,000 |
|
|
|
| General Operation [Member] |
|
|
|
|
| Estimated Projected Expenditure Type [Line Items] |
|
|
|
|
| Projected expenditures for clinical programs |
3,800,000 |
|
|
|
| Other General and Administrative Expenses [Member] |
|
|
|
|
| Estimated Projected Expenditure Type [Line Items] |
|
|
|
|
| Projected expenditures for clinical programs |
$ 8,900,000 |
|
|
|